Hepatectomy After Conversion Therapy with Hepatic Arterial Infusion Chemotherapy, Tyrosine Kinase Inhibitors and Anti-PD-1 Antibodies for Initially Unresectable Hepatocellular Carcinoma

• DOI: 10.2147/jhc.s432062
• Publication Date: 2023-10-04T05:00:12Z
• Authors: Bingran Yu; Ning Zhang; Yun Feng; Yongfa Zhang; Ti Zhang; Lu Wang
• Keywords: hepatectomy; pathological complete response; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; hepatocellular carcinoma; conversion therapy; Journal of Hepatocellular Carcinoma; RC254-282; 3. Good health; Original Research

Most patients with hepatocellular carcinoma (HCC) are not candidates for liver resection. We investigated the clinicopathological characteristics and prognosis of initially unresectable HCC who underwent hepatectomy after conversion therapy hepatic arterial infusion chemotherapy (HAIC), tyrosine kinase inhibitors (TKIs), anti-PD-1 antibodies.Patients received HAIC combined TKIs antibodies followed by between December 2020 2022, were retrospectively analyzed. Patient characteristics, tumor treatment efficacy, perioperative pathological survival outcomes summarized analyzed.67 enrolled in this study. Patients treated 3 sessions (range:2-6 sessions) combination performed 4 months (range:1.4-17.8 months) initiation therapy. The median size shrinkage was 4.7 cm (range:0.9-11.7 cm). A complete response (pCR) achieved 34.3% (n = 23). recurrence-free (RFS) 19.3 overall (OS) 28.7 months. pCR had a better RFS (P 0.004) those without microscopic vascular invasion (MVI) (RFS, P 0.011; OS, 0.023). Multivariable logistic analysis revealed that number associated pCR.Hepatectomy HAIC, TKIs, is feasible strategy HCC. This promising prognosis.